Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration

Nobuhiro Kato, Masatoshi Haruta, Kei Furushima, Rikki Arai, Yu Matsuo, Shigeo Yoshida Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanCorrespondence: Masatoshi Haruta, Department of Ophthalmology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka,...

Full description

Bibliographic Details
Main Authors: Kato N, Haruta M, Furushima K, Arai R, Matsuo Y, Yoshida S
Format: Article
Language:English
Published: Dove Medical Press 2023-04-01
Series:Clinical Ophthalmology
Subjects:
Online Access:https://www.dovepress.com/decrease-in-ocular-blood-flow-thirty-minutes-after-intravitreal-inject-peer-reviewed-fulltext-article-OPTH
_version_ 1797844477993287680
author Kato N
Haruta M
Furushima K
Arai R
Matsuo Y
Yoshida S
author_facet Kato N
Haruta M
Furushima K
Arai R
Matsuo Y
Yoshida S
author_sort Kato N
collection DOAJ
description Nobuhiro Kato, Masatoshi Haruta, Kei Furushima, Rikki Arai, Yu Matsuo, Shigeo Yoshida Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanCorrespondence: Masatoshi Haruta, Department of Ophthalmology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan, Tel +81 942 31 7574, Fax +81 942 37 0324, Email haruta_masatoshi@med.kurume-u.ac.jpPurpose: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as brolucizumab and aflibercept are used widely to treat neovascular age-related macular degeneration (nAMD); however; they may theoretically affect the ocular blood flow. We investigated the short-term changes in the ocular blood flow between eyes with nAMD treated with intravitreal brolucizumab injections (IVBr) and intravitreal aflibercept injections (IVA).Methods: This study included 21 eyes of 21 Japanese patients with nAMD treated with either IVBr or IVA at Kurume University Hospital from April 2021 through June 2022. The rates of ocular blood flow at the optic nerve head (ONH mean blur rate [MBR]-vessel) and at the choroid (CHOR MBR) were analyzed before and 30 minutes after injections using laser speckle flowgraphy.Results: In the IVBr-treated group, the ONH MBR-vessel and CHOR MBR rates decreased significantly by 10.6% and 16.9% from baseline to 30 minutes after IVBr, respectively. In the IVA-treated group, ONH MBR-vessel and CHOR MBR rates decreased significantly by 9.4% and 6.1% from baseline to 30 minutes after IVA, respectively. There was no significant difference in the rates of decrease in the ONH MBR-vessel or CHOR MBR between the IVBr-treated and IVA-treated groups.Conclusion: Intravitreal injections of brolucizumab and aflibercept in eyes with nAMD cause significant decreases in ocular blood flow at the ONH and the choroid 30 minutes after injection. The rate of decrease in ocular blood flow was not significant between the eyes treated with brolucizumab and aflibercept. However, 3 of 10 eyes treated with brolucizumab but none of 11 eyes treated with aflibercept had more than a 30% decrease in the ocular blood flow at the choroid 30 minutes after injection.Keywords: anti-vascular endothelial growth factor agents, choroid, laser speckle flowgraphy, mean blur rate, optic nerve head
first_indexed 2024-04-09T17:22:57Z
format Article
id doaj.art-9807aa0ec1994bb4bb3ebbda3fbc1131
institution Directory Open Access Journal
issn 1177-5483
language English
last_indexed 2024-04-09T17:22:57Z
publishDate 2023-04-01
publisher Dove Medical Press
record_format Article
series Clinical Ophthalmology
spelling doaj.art-9807aa0ec1994bb4bb3ebbda3fbc11312023-04-18T19:32:08ZengDove Medical PressClinical Ophthalmology1177-54832023-04-01Volume 171187119283133Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular DegenerationKato NHaruta MFurushima KArai RMatsuo YYoshida SNobuhiro Kato, Masatoshi Haruta, Kei Furushima, Rikki Arai, Yu Matsuo, Shigeo Yoshida Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanCorrespondence: Masatoshi Haruta, Department of Ophthalmology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan, Tel +81 942 31 7574, Fax +81 942 37 0324, Email haruta_masatoshi@med.kurume-u.ac.jpPurpose: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as brolucizumab and aflibercept are used widely to treat neovascular age-related macular degeneration (nAMD); however; they may theoretically affect the ocular blood flow. We investigated the short-term changes in the ocular blood flow between eyes with nAMD treated with intravitreal brolucizumab injections (IVBr) and intravitreal aflibercept injections (IVA).Methods: This study included 21 eyes of 21 Japanese patients with nAMD treated with either IVBr or IVA at Kurume University Hospital from April 2021 through June 2022. The rates of ocular blood flow at the optic nerve head (ONH mean blur rate [MBR]-vessel) and at the choroid (CHOR MBR) were analyzed before and 30 minutes after injections using laser speckle flowgraphy.Results: In the IVBr-treated group, the ONH MBR-vessel and CHOR MBR rates decreased significantly by 10.6% and 16.9% from baseline to 30 minutes after IVBr, respectively. In the IVA-treated group, ONH MBR-vessel and CHOR MBR rates decreased significantly by 9.4% and 6.1% from baseline to 30 minutes after IVA, respectively. There was no significant difference in the rates of decrease in the ONH MBR-vessel or CHOR MBR between the IVBr-treated and IVA-treated groups.Conclusion: Intravitreal injections of brolucizumab and aflibercept in eyes with nAMD cause significant decreases in ocular blood flow at the ONH and the choroid 30 minutes after injection. The rate of decrease in ocular blood flow was not significant between the eyes treated with brolucizumab and aflibercept. However, 3 of 10 eyes treated with brolucizumab but none of 11 eyes treated with aflibercept had more than a 30% decrease in the ocular blood flow at the choroid 30 minutes after injection.Keywords: anti-vascular endothelial growth factor agents, choroid, laser speckle flowgraphy, mean blur rate, optic nerve headhttps://www.dovepress.com/decrease-in-ocular-blood-flow-thirty-minutes-after-intravitreal-inject-peer-reviewed-fulltext-article-OPTHanti-vascular endothelial growth factor agentschoroidlaser speckle flowgraphymean blur rateoptic nerve head
spellingShingle Kato N
Haruta M
Furushima K
Arai R
Matsuo Y
Yoshida S
Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
Clinical Ophthalmology
anti-vascular endothelial growth factor agents
choroid
laser speckle flowgraphy
mean blur rate
optic nerve head
title Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
title_full Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
title_fullStr Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
title_full_unstemmed Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
title_short Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
title_sort decrease in ocular blood flow thirty minutes after intravitreal injections of brolucizumab and aflibercept for neovascular age related macular degeneration
topic anti-vascular endothelial growth factor agents
choroid
laser speckle flowgraphy
mean blur rate
optic nerve head
url https://www.dovepress.com/decrease-in-ocular-blood-flow-thirty-minutes-after-intravitreal-inject-peer-reviewed-fulltext-article-OPTH
work_keys_str_mv AT katon decreaseinocularbloodflowthirtyminutesafterintravitrealinjectionsofbrolucizumabandafliberceptforneovascularagerelatedmaculardegeneration
AT harutam decreaseinocularbloodflowthirtyminutesafterintravitrealinjectionsofbrolucizumabandafliberceptforneovascularagerelatedmaculardegeneration
AT furushimak decreaseinocularbloodflowthirtyminutesafterintravitrealinjectionsofbrolucizumabandafliberceptforneovascularagerelatedmaculardegeneration
AT arair decreaseinocularbloodflowthirtyminutesafterintravitrealinjectionsofbrolucizumabandafliberceptforneovascularagerelatedmaculardegeneration
AT matsuoy decreaseinocularbloodflowthirtyminutesafterintravitrealinjectionsofbrolucizumabandafliberceptforneovascularagerelatedmaculardegeneration
AT yoshidas decreaseinocularbloodflowthirtyminutesafterintravitrealinjectionsofbrolucizumabandafliberceptforneovascularagerelatedmaculardegeneration